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Abstract
Cystic Fibrosis (CF) is one of the most common autosomal genetic disorders in humans. This
disease is caused by mutations within a single gene, coding for the cystic fibrosis transmembrane
conductance regulator (CFTR) protein. The phenotypic hallmark of CF is chronic lung infection and
associated inflammation from opportunistic microbes such as Pseudomonas aeruginosa (PA),
Haemophilus influenzae, and Staphylococcus aureus. This eventually leads to deterioration of lung
function and death in most CF patients. Unfortunately, there is no approved therapy for correcting
the genetic defect causal to the disease. Hence, controlling inflammation and infection in CF
patients are critical to disease management. Accordingly, anti-inflammatory agents and antibiotics
are used to manage chronic inflammation and infection in CF patients. However, most of the anti-
inflammatory agents in CF have severe limitations due to adverse side effects, and resistance to
antibiotics is becoming an even more prominent problem. Thus, new agents that can be used to
control chronic inflammation in CF are needed in the absence of a cure for the disease. Activation
of the transcription factor NFκB through Toll-like receptors (TLR) following bacterial infection is
principally involved in regulating lung inflammation in CF. NFκB regulates the transcription of
several genes that are involved in inflammation, anti-apoptosis and anti-microbial activity, and
hyper-activation of this transcription factor leads to a potent inflammatory response. Thus, NFκB
is a potential anti-inflammatory drug target in CF. Screening of several compounds from natural
sources in an in vitro model of CF-related inflammation wherein NFκB is activated by filtrates of a
clinically isolated strain of PA (PAF) led us to Withaferin A (WFA), a steroidal lactone from the
plant Withania Somnifera L. Dunal. Our data demonstrate that WFA blocks PAF-induced activation
of NFκB as determined using reporter assays, IL-8 measurements and high-content fluorescent
imaging of NFκB subunit p65 translocation. Since the airways of CF patients can be specifically
targeted for delivery of therapeutics, we propose that WFA should be further studied as an anti-
inflammatory agent in models of CF related inflammation mediated by NFκB.
Findings
Cystic Fibrosis (CF) is one of the most common lethal
autosomal recessive diseases in humans. It is caused by
mutations within a single gene, coding for the cystic fibro-
sis transmembrane conductance regulator (CFTR) protein
(reviewed in [1]). Loss of lung function causes over 90%
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of all CF deaths [2,3], which is brought about by chronic
bacterial infections involving drug-resistant pathogenic
strains of Pseudomonas aeruginosa (PA), Haemophilus influ-
enzae  and  Staphylococcus aureus [3-5] among others.
Chronic and uncontrolled stimulation of cellular signal-
ing by bacterial products through toll-like receptors
(TLRs) lead to hyper-activation of the transcription factor
NFκB and over-expression of a number of pro-inflamma-
tory cytokines [6-8]. Consequently, an overwhelming
number of neutrophils and macrophages are attracted to
the site of infection and these cells release proteases and
other agents that cause structural damage to the airways.
Anti-inflammatory agents are used to manage lung
inflammation in CF, but have adverse effects [9] that limit
their use. Thus, there is a need to identify drugs with lim-
ited toxicity to treat lung inflammation in CF [10].
Screening of natural products with purported anti-inflam-
matory activity led us to Withaferin A (WFA), a steroidal
lactone isolated from the herb Withania somnifera (also
known as Indian Ginseng and Ashwagandha), which is
widely used in traditional Indian medicine as an anti-
inflammatory agent [11]. Recent reports indicate that this
natural product is an inhibitor of NFκB activity [12,13].
The overall goal of this study was to characterize the effect
of this compound on NFκB in cellular models of CF-
related inflammation. In our studies, filtrates of PA iso-
lated from a CF patient were used. This is an established
method to experimentally induce inflammation in the
field of CF research and is relevant to airway inflamma-
tion noted in patients [14,15]. Inflammation in CF is
caused by a complex mixture of bacterial products includ-
ing secreted toxins, lipoproteins, lipopolysaccharides and
bacterial DNA [16]. The filtrates used in our studies iso-
lated from post log-phase cultures of PA contain many of
these harmful agents. These products differentially acti-
vate various TLRs expressed in airway epithelial cells and
ultimately increase expression of pro-inflammatory genes
regulated by NFκB [17].
Unless specified, all reagents were purchased from Sigma
Aldrich (St. Louis Missouri). The KKLEB immortalized CF
airway cell line homozygous for ΔF508 mutation and the
CF 14 clinically isolated mucoid strain of PA (originally
from the laboratory of Dr. M.C. Wolfgang, University of
North Carolina) were donated by Dr. S. Randell (Univer-
sity of North Carolina) [15]. HEK 293 cells were obtained
from ATCC (Manassas, VA). Cells were maintained in
DMEM/F12 medium with 10% fetal bovine serum and
antibiotics. A NFκB reporter plasmid was constructed as
follows: Complementary oligonucleotides bearing NFκB
consensus DNA-binding sequence (5'-gctagc tgg gga ctt tcc
gct ggg gac ttt ccg ctg ggg act ttc cgc tgg gga ctt tcc gct ggg
gac ttt ccg c aagctt-3') were synthesized with flanking NheI
and HindIII sites (underlined), annealed and introduced
into the pGL4.26 (luc2/minP/Hygro) vector (Promega,
Madison, WI). The construct was linearized with Bsu36I
and transfected into HEK293 cells using Fugene HD
(Roche Diagnostics, Indianapolis, IN). Clonal cell-lines
stably expressing the construct were identified following
selection in Hygromycin-containing media and tested for
NFκB-mediated induction of luciferase reporter activity
using recombinant TNF-α and filtrates of a clinically iso-
lated mucoid strain of PA (PAF) from a CF patient (data
not shown). A stable cell line designated HEK293/NFκB-
luc was used for the reported experiments. For transient
transfection assays, KKLEB cells were batch transfected
using Fugene HD reagent in suspension and subsequently
plated out into 24-well plates. This approach nullified the
need to use a second reporter gene for data normalization.
Unless otherwise noted, cells were allowed to incubate
overnight and then induced with PAF for 24 hr in serum-
containing media. Typically, cells were pre-incubated with
WFA (Chromadex, Santa Ana, CA) for 2 hr and then stim-
ulated with PAF that were prepared essentially as
described previously [15]. Briefly, the clinically isolated
mucoid strain of PA was grown for 72 hr in LB media. The
supernatant from the culture was removed by centrifuga-
tion, boiled for 10 min to inactivate proteolytic activity,
aliquoted, and stored at -80°C. Luciferase assays were
conducted using a kit obtained from Promega in a TECAN
plate-reader. Quantification of IL-8 in media was per-
formed using a commercially available sandwich ELISA
WFA pre-treatment inhibits NFκB reporter activity in  HEK293/NFκB-luc cells stimulated with PAF Figure 1
WFA pre-treatment inhibits NFκB reporter activity 
in HEK293/NFκB-luc cells stimulated with PAF. Cells 
were plated and treated as described in the "Findings" sec-
tion. Treatment groups were as follows: Cells treated with 
media only (Control), cells treated with media containing 
10% LB Broth (LB), cells treated with 10% PAF (PAF), cells 
pre-treated with various concentrations of WFA followed by 
stimulation with 10% PAF (WFA, 0.3, 1 and 3 μM). Data from 
luciferase reporter assays are reported as averaged arbitrary 
mean luminescence + standard deviation from 6 samples per 
group. Withaferin pre-treated samples were compared to 
PAF-treated samples using Student's t-test. Statistical signifi-
cance was noted at 1 and 3 μM concentrations in WFA pre-
treated cells compared to PAF only cells as indicated.Journal of Inflammation 2009, 6:15 http://www.journal-inflammation.com/content/6/1/15
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kit (Biolegend Inc., San Diego, CA). For the NFκB subunit
p65 translocation studies using immunofluorescence
microscopy, KKLEB cells were seeded in black optical-bot-
tom 96-well plates and treated as described above with
PAF and WFA. Following treatment, cells were fixed with
3.7% formaldehyde in PBS, and fluorescently labeled
using a commercially available kit (NFκB activation HCS
kit, Thermo Scientific, Waltham, MA). Fluorescent images
were acquired at 20× magnification using a Discovery 1
automated fluorescent microscope (MDS Analytical
Devices) with filter sets appropriate for FITC (for p65
detection) and DAPI (nuclear stain). Six images were ana-
lyzed per group resulting in analysis of roughly 300 cells
per treatment. Nuclear translocation of p65 was measured
using the enhanced translocation module from the Metax-
press image analysis software provided with the instru-
ment. Input settings delineating cell "compartment"
(nucleus) and "regions for measurement" (cytoplasm)
were entered as follows: Compartment-width = 10 μm,
intensity above background = 200 gray levels, minimum
area = 5 μm2, and maximum area = 1000 μm2. Regions for
Measurement (RFM) were entered as follows: Inner region
distance from edge = 1 μm, outer region distance from
edge = 1 μm, outer region width = 6 μm, background cor-
rection = none. Cells were scored as positive for nuclear
translocation of p65 if the correlation coefficient was 0.75
or greater. Cell viability was monitored using the Cell-
Titer Glo Luminescent Cell Viability Assay (Promega Cor-
poration) following the manufacturer's suggestion. All
concentrations used for our studies were non-cytotoxic to
the cells (data not shown) under the experimental condi-
tions.
An NFκB-responsive luciferase reporter construct was
used to test the hypothesis that PAF-stimulated NFκB
activity diminished upon treatment with WFA. As demon-
strated in Figure 1, WFA pre-treatment significantly inhib-
ited NFκB luciferase reporter activity stimulated by PAF in
a concentration-dependent fashion by as much as 70% in
HEK293/NFκB-luc cells. Past reports indicate that
HEK293 cells express certain TLR isoforms that were acti-
vated by bacterial factors present in PAF used for our stud-
ies leading to NFκB reporter activity [18,19]. Further
testing of WFA was conducted in a more relevant in vitro
model of CF inflammation. In this model, the immortal-
ized CF epithelial cell line KKLEB harboring the most
common and severe CFTR mutation (ΔF508, noted in >
90% CF patients) was stimulated with PAF and NFκB
activity was subsequently measured using three different
methods. First, a transiently transfected luciferase reporter
was used to monitor NFκB activation by PAF with or with-
out WFA pre-treatment. As reported in Figure 2, WFA pre-
treatment significantly diminished luciferase activity com-
pared to control groups in a concentration-dependent
WFA pre-treatment inhibits IL-8 secretion from KKLEB cells  stimulated with PAF Figure 3
WFA pre-treatment inhibits IL-8 secretion from 
KKLEB cells stimulated with PAF. Cells were plated and 
treated as described in the "Findings" section. Treatment 
groups were as follows: Cells with media only (Untreated), 
cells treated with media containing 10% LB Broth (LB), cells 
treated with 10% PAF (PAF), cells pre-treated with various 
concentrations of WFA followed by stimulation with 10% 
PAF (WFA, 0.3, 1 and 3 μM). After 24 hr of incubation, 
media from each sample was collected and analyzed for IL-8 
secretion using ELISA. Concentration of IL-8 was calculated 
by fitting the optical density of each sample to a standard 
curve prepared with recombinant IL-8 using linear regres-
sion. Data are reported as mean IL-8 secretion + standard 
deviation averaged from 3 samples per group. Withaferin 
pre-treated samples were compared to PAF-treated samples 
using Student's t-test. Statistical significance was noted at 3 
μM as indicated.
WFA pre-treatment inhibits NFκB reporter activity in tran- siently transfected KKLEB cells stimulated with PAF Figure 2
WFA pre-treatment inhibits NFκB reporter activity 
in transiently transfected KKLEB cells stimulated 
with PAF. Cells were plated and treated as described in the 
"Findings" section. Treatment groups were as follows: Cells 
with media only (Untreated), cells treated with media con-
taining 10% LB Broth (LB), cells treated with 10% PAF (PAF), 
cells pre-treated with various concentrations of WFA fol-
lowed by stimulation with 10% PAF (WFA, 0.3, 1 and 3 μM). 
Data from luciferase reporter assays are reported as aver-
aged arbitrary mean luminescence + standard deviation from 
3 samples per group. Withaferin pre-treated samples were 
compared to PAF-treated samples using Student's t-test. Sta-
tistical significance was noted at 3 μM concentrations in 
WFA pre-treated cells compared to PAF only cells as indi-
cated.Journal of Inflammation 2009, 6:15 http://www.journal-inflammation.com/content/6/1/15
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fashion by ~70% in the KKLEB cells. Inflammation in CF
is regulated largely by activation of NFκB and transcrip-
tion of pro-inflammatory genes regulated by this tran-
scription factor [16,20]. Therefore, we examined the effect
of WFA pre-treatment on IL-8 secretion upon challenge
with 10% PAF in KKLEB cells using ELISA. Inhibition of
PAF-stimulated secretion of IL-8 protein was noted upon
pre-treatment with WFA (Figure 3) by ~50% in KKLEB
cells in agreement with reporter assays.
The term NFκB commonly refers to a p50–p65 het-
erodimer, which is the major Rel/NFκB complex in most
cells [21,22]. In order to further characterize inhibition of
NFκB by WFA, we investigated the effect of WFA on trans-
location of the NFκB subunit p65 upon stimulation with
PAF using high-content immunofluorescence imaging
(Figure 4). WFA pre-treatment clearly inhibited p65 trans-
location into the nucleus in KKLEB cells (Figure 4, bottom
panel). Quantification of the images indicated that trans-
location of p65 was inhibited by > 80% in cells pre-treated
with WFA (Figure 5).
CF as a disease is largely limited to Caucasians. According
to a recent report, ~30% of patients suffering from pro-
gressive medical conditions including CF use comple-
mentary and alternative approaches to supplement
conventional therapies [23]. We are intrigued by this find-
ing, as there are many promising anti-inflammatory and
anti-bacterial ethnopharmacological agents that have not
been adequately studied in the context of diseases that are
atypical in native populations, such as CF, where they may
provide a benefit. Thus, our long-term goal is to develop
strategies and platforms to test such agents in CF and
other diseases. Our studies with WFA demonstrate the
potential of natural products in preventing inflammation
in CF mediated by NFκB. WFA itself is toxic to cells at high
concentrations [24] but not at the concentrations used in
this study. However, other less toxic withanolides [25]
from W. somnifera may be useful as early leads to treat
Quantification of p65 translocation upon PAF stimulation and  inhibition by WFA Figure 5
Quantification of p65 translocation upon PAF stimu-
lation and inhibition by WFA. Quantification of p65 
translocation into nuclei of KKLEB cells under various test 
conditions was performed as described in "Findings". Treat-
ment groups are as follows: Cells with media only (Media), 
cells treated with media containing LB Broth (LB), cells 
treated with 10% PAF (PAF), cells treated with 25 ng/ml 
TNF-α (TNF-α). All groups were either pre-treated with 
vehicle (WFA (-)) or with 3 μM WFA (WFA (+)). Data are 
reported as percent mean + standard deviation of cells 
scored as positive for p65 translocation. The treated sample 
groups were statistically different from untreated sample 
groups as determined using two-way ANOVA (p < 0.05). 
Pair-wise comparisons between groups were performed 
using Bonferroni post-tests. Statistical significance (if applica-
ble) was noted on the figure. Statistical tests were performed 
using Prism software (GraphPad, La Jolla, CA).
WFA pre-treatment inhibits nuclear translocation of NFκB  subunit p65 in KKLEB cells stimulated with PAF Figure 4
WFA pre-treatment inhibits nuclear translocation of 
NFκB subunit p65 in KKLEB cells stimulated with 
PAF. Cells were plated out, treated and immunostained for 
fluorescence microscopy in optical-bottom 96-well plates as 
described in "Findings". Images of fixed cells were captured 
using a Discovery 1 system at 20× magnification under identi-
cal conditions across all sample wells. The images were not 
digitally processed prior to analyses. Six images were ana-
lyzed per group. Representative images are shown. For pres-
entation, images were imported into Image J (NIH, Bethesda, 
MD) and pseudocolored. A FITC-conjugated antibody was 
used to detect p65 (left set of columns, pseudocolered 
green) and DAPI was used to delineate the nuclei of each cell 
(middle set of columns, pseudocolored red). Merged images 
are shown in the right column. Images are grouped as follows 
(top to bottom rows): Control cells treated with media con-
taining 10% LB Broth (LB), cells treated with 10% PAF (PAF), 
cells pre-treated with WFA (3 μM) followed by stimulation 
with 10% PAF (WFA + PAF). Translocation of p65 to the 
nucleus is clearly noted upon treatment with PAF. Transloca-
tion of p65 is inhibited by WFA pre-treatment leading to 
decreased FITC-associated fluorescence in nuclei of KKLEB 
cells as demonstrated in the bottom row.Publish with BioMed Central    and   every 
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inflammation in CF. Alternatively, structure activity stud-
ies of WFA using medicinal chemistry may lead to com-
pounds that inhibit NFκB activity without undesirable
side effects. Further, targeted delivery of anti-NFκB agents
to the airways of CF patients is possible using inhaled aer-
osols [26], which would restrict their effects largely to tar-
get tissues where this transcription factor is reported to be
hyper-activated. We propose to explore some of these pos-
sibilities in future studies.
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